Provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin ...
Today announced that Blair McInnis has provided notice of his resignation as Chief Financial Officer ...
Announced that it has closed its previously announced “bought deal” private placement of 9.0% convertible ...
Announced that in connection with its previously announced bought deal private placement financing, ...
Today announced its financial results for the second quarter ended June 30, 2023. Revenue was $306,000 ...
Announced its financial results for the second quarter ended June 30, 2022. Revenue for the three-months ...
Announced that Dialco, along with its distribution partner, Marathon Medical Corporation, have been ...
Announced that Dr. John Kellum, Spectral’s Chief Medical Officer, will be the featured speaker in a ...
Video replay of sponsored symposium explaining endotoxemic septic shock and the case for hemoperfusion therapy...
Announced that Chris Seto, CEO, and Dr. John Kellum, CMO, of Spectral Medical, will be participating ...